FK866, a non-competitive inhibitor of NAMPT, has been shown to reduce NAD+ levels and suppress glycolysis in human leukemia cells [12–14], reduce viability of both solid and hematologic cancers [5,9,15], and reduce leukemic disease burden in vivo [16]. Here, NAMPT is linked to leukemia.